Nasdaq:US$13.40 (+0.13) | HKEX:HK$21.30 (+0.25) | AIM:£2.08 (-0.01)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors